PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
56.39
Positive P/E while Drug Manufacturers - Specialty & Generic median is negative at -1.13. Peter Lynch would investigate competitive advantages in a distressed Drug Manufacturers - Specialty & Generic.
53.30
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.78. Jim Chanos would check for potential multiple compression risks.
1.70
P/B near Drug Manufacturers - Specialty & Generic median of 1.70. Charlie Munger would verify if similar multiples reflect similar business quality.
28092.70
Positive FCF while Drug Manufacturers - Specialty & Generic median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
1237.87
P/OCF of 1237.87 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
1.70
Fair value ratio near Drug Manufacturers - Specialty & Generic median of 1.70. Charlie Munger would verify if industry valuation norms make sense.
0.44%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
0.00%
Positive FCF while Drug Manufacturers - Specialty & Generic median shows negative FCF. Peter Lynch would examine cash generation advantage.